Bioperfectus

Executive Summary

Bioperfectus is a leading Chinese biotechnology company specializing in molecular diagnostics for infectious diseases, genetics, and genomics. Founded in 2009 and headquartered in Taizhou, the company develops and manufactures PCR systems, nucleic acid extraction instruments, and diagnostic reagents. With over 500 employees, Bioperfectus has established itself as a key supplier for public health surveillance, particularly in emerging infectious disease detection. The company's product portfolio includes PCR platforms, automated extraction systems, and a wide range of reagent kits for respiratory pathogens, sexually transmitted infections, and genetic disorders. Its strong presence in China's diagnostic market is supported by regulatory approvals from the NMPA and collaborations with hospitals and CDC networks. Bioperfectus is well-positioned to benefit from the growing demand for rapid, accurate molecular diagnostics, especially in the context of pandemic preparedness and routine infection control. The company continues to invest in R&D to expand its menu of tests and improve automation, targeting both domestic and international markets. While privately held, Bioperfectus demonstrates consistent commercial traction and strategic importance in China's healthcare ecosystem.

Upcoming Catalysts (preview)

• Q3 2026Launch of new multiplex PCR panel for respiratory infections70% success
• H2 2026NMPA approval for next-generation nucleic acid extraction system80% success
• 2026Strategic partnership with WHO or major public health agency for outbreak surveillance60% success